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Abstract While short-acting j82-agonists are seen as the cornerstone of treatment as relief medication for asthma, 
current guidelines recommend long-acting ~2-agonists as maintenance therapy in combination with inhaled corticoster- 
oids in patients with moderate to severe asthma, poorly controlled on present treatment. Although evidence has shown 
that formoterol, with its fast- and long-acting profile, is effective when used both as regular and as-needed therapy in all 
types of asthma, there has been some concern about the potential of/~2-agonists with long-acting profiles to produce 
side effects with a longer duration than seen with short-acting ~2-agonists. Also, where formoterol is used as needed, a 
higher total daily dose would be anticipated than when taken twice daily for regular maintenance therapy and this again 
has led to some concern. In a number of studies, formoterol has been shown to be well tolerated, and although systemic 
effects expected with this class of drugs did occur, formoterol had significantly less effect on serum potassium, pulse, 
blood pressure, cardiac frequency and QT interval compared with terbutaline. In addition, the duration of effects was 
equivalent o that observed with terbutaline and salbutamol and the relative therapeutic index offormoterol compared 
with salbutamol was found to be 2.5. Furthermore, studies looking at long-term use offormoterol have shown there is no 
reduction in bronchodilatory effect, and thus, no development of tolerance. In conclusion, formoterol is well tolerated in 
high doses, producing side effects typical of its class, but with a duration no longer than occurs with short-acting/~2- 
agonists.These observations, and the lack of tolerance development, suggest that formoterol ma/be appropriate treat- 
ment for patients with asthma of all types and severities on an as-needed basis or as regular treatment. 
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INTRODUCTION 
~2-agonists, particularly salbutamol, have been in wide- 
spread clinical use since the 1970s and are seen as the cor- 
nerstone of treatment in mildly asthmatic patients and in 
acute attacks (I). They offer rapid bronchodilation and 
are generally well tolerated. The unwanted effects of 
/~2-agonists are well known, predictable extensions to 
the group's pharmacology, including tremor, tachycardia 
and hypokalaemia. It appears that relaxation of bronchial 
smooth muscle, relaxation of vascular smooth muscle 
and enhancement of physiological tremor are all a result 
of activation of the ~2-receptor, and without further 
sub-classification of this receptor it is unlikely that these 
class effects will be reduced (2). However,/82-agonists are 
generally well tolerated and patients have been treated 
successfully with these drugs for many years. 
Formoterol is a B2-agonist with a specific pharmacolo- 
gical profile, resulting in both a fast onset and a long 
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duration of action (3). It has been shown in a number of 
studies to have an onset of action comparable with short- 
acting/82-agonists, such as salbutamol (4,5), but with a 
long-lasting duration of action similar to that of salme- 
terol (5-7). 
There has been some debate about the safety of ~z- 
agonists, particularly when considering regular vs. as- 
needed use of these drugs. These concerns arose follow- 
ing increased mortality in New Zealand (8). In view of 
this, the first British guidelines for the treatment of asth- 
ma recommended the use of/~2-agonists only on an as- 
needed basis following research suggesting that regular 
use may cause increased mortality and morbidity, and 
may result in poorer asthma control than when used as 
relief medication (9,10). A possible explanation for such 
observations is that ~2-agonist use increases with disease 
severity and as the dose increases more side effects are 
observed (11). More recently a number of studies have 
been published that show/~2-agonists are well tolerated 
when used as needed (12,13). 
Although clinical studies with formoterol have shown 
it to be well tolerated, it would be expected to exhibit 
the unwanted effects of the ~2-agonist class. There are 
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two main theoretical concerns about the safety of for- 
moterol. First, as a/?2-agonist with a long-acting profile, 
there are concerns that any expected systemic side ef- 
fects might have a longer duration with formoterol. Sec- 
ond, where formoterol is used as needed, a higher dose 
would be anticipated than when taken as regular mainte- 
nance therapy twice daily. An additional consideration is 
whether formoterol used on an as-needed basis is likely 
to result in a greater or clinically relevant degree of toler- 
ance than short-acting fl2-agonists. 
SYSTEMIC EFFECTS WITH 
FORMOTEROL 
The effect of taking high doses is an important consid- 
eration in the selection of a relief medication since it is 
likely that some patients will take extra inhalations, 
either on purpose or by mistake. The effects of formo- 
terol 901tg, divided into six 15/zg administrations over 
3 h, were compared with terbutaline I0 mg, also divided 
into six administrations, in patients with acute broncho- 
constriction (14). This dose of formoterol is much higher 
than the maximum dose normally taken with twice-daily 
maintenance therapy. Patients with acute bronchocon- 
striction (forced expiratory volume in I second [FEVI] 
20-50% of predicted normal value) were recruited. All 
patients received intravenous prednisolone after 1.5h 
and oxygen during the first 3 h. Patients were then as- 
sessed for 12 h following the start of study drug. Lung 
function, measured by FEVb improved to the same ex- 
tent in both groups, indicating equipotent efficacy, but 
although mean serum potassium levels dropped in both 
treatment groups, this effect was statistically signifi- 
cantly greater following terbutaline. In addition, heart 
rate increased to a statistically significant greater degree 
following terbutaline compared with formoterol. 
Although high quantities of both drugs were used, re- 
flecting clinical practice, it was concluded that formoter- 
ol in doses up to 90fig was safe and well tolerated in 
patients with acute bronchoconstriction. 
In another study the effects of high doses of formoter- 
ol delivered viaTurbuhale¢ ~' were again compared with 
high doses of terbutaline in a crossover design study (15). 
In this study, patients were treated with formoterol 
54#g total daily dose or terbutaline 6 mg in three doses 
given in the morning, after lunch and in the evening for 
three consecutive days, to mimic clinical practice. As 
these doses were well tolerated, patients went on to re- 
ceive treatment in the second part of the study with 
either formoterol 90/~g or terbutaline l0 mg, again given 
three times during the day. Pulse, cardiac frequency, 
blood pressure, serum potassium, electrocardiogram 
and FEVI were measured at regular intervals and Holter 
monitoring was applied during each of the treatment 
days. No differences in FEVI levels were found between 
groups, and both drugs were generally well tolerated. 
However, in the first part of the study, terbutaline 
showed statistically significant greater effects than for- 
moterol on pulse, blood pressure, cardiac frequency 
and QT interval corrected for heart rate (QTc). In the 
second part of the study, using higher doses, statistically 
significant differences favouring formoterol were also 
observed in serum potassium levels, pulse, cardiac fre- 
quency and QTc. The fact that formoterol resulted in 
fewer systemic effects using the same number of inhala- 
tions was considered important by the authors, as pa- 
tients used to taking a defined number of inhalations 
from one inhaler are likely to take the same number of 
doses from any different inhaler in the treatment of an 
acute attack. Interestingly, the time course for changes 
in systemic effects was similar for both formoterol and 
terbutaline (Fig. I). Hence, even though the duration of 
bronchodilation achieved with each drug is different, for- 
moterol producing a long bronchodilatory effect, terbu- 
taline a short-lasting effect, systemically they both 
appear to be short acting. 
The short duration of systemic effects of formoterol 
were also shown in a study comparing the effects of 
twice-daily formoterol with salbutamol (16). Both agents 
caused dose-dependant systemic effects--serum potas- 
sium concentration and diastolic blood pressure de- 
creased, plasma concentrations of glucose and lactate, 
pulse, systolic blood pressure and QTc increased. Equi- 
effective cumulative doses of formoterol 54#g and sal- 
butamol 3600 #g were shown to have a similar duration 
of effect on systemic effects. In a different study, formo- 
terol has been shown to be 215 times as potent as salbu- 
tamol on a microgram for microgram basis with respect 
to bronchodilation, yet only 88 times more potent with 
regard to suppression of serum potassium (17).The rela- 
tive therapeutic index, based on bronchodilation and ser- 
um potassium suppression, was estimated to be 2.5 in 
favour of formoterol. 
! . t i "  v:' 
3 8 [ i" ~ Oxis Turbuhaler '~54 mg / day 
3.6 ~ .......... Terbutaline Turbuhaler ®6 mg / day 
ta 3 .4 f  il Dosing time i 
1 2 3 4 
Days 
Figure I. Changes in serum potassium in patients receiving 
high doses offormoterot and terbutaline (15), 
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In a dose-response study in normal subjects looking at 
the effects of inhaled formoterol and salmeterol, both 
drugs were shown to exhibit systemic effects due to in- 
teraction with/~2-receptors other than those in the air- 
ways, i.e. decreased potassium levels, a small increase in 
glucose and vascular effects such as increased heart rate 
and changes in blood pressure (18). In general, systemic 
effects lasted longer in subjects receiving salmeterol 
compared with formoterol. 
An area that may require further research concerns 
patients with pre-existing cardiac disorders (19). Patients 
with chronic obstructive pulmonary disease who also 
suffered from arrhythmias and hypoxia were shown to 
have a higher incidence of supraventricular or ventricular 
premature beats following treatment with a high dose of 
formoterol (241~g metered dose) compared with treat- 
ment with formotero112 #g or salmetero150 #&The clin- 
ical significance of this result is not clear, but may 
confirm that care is needed when /~2-agonists are pre- 
scribed to patients with significant comorbidity. This re- 
sult is of equal relevance for treatment with salbutamol 
and formoterol as needed. 
LONG-TERM TREATMENT WITH 
FORMOTEROL 
/~2-agonists have been shown to cause tolerance when 
given regularly, resulting in a loss of bronchoprotection 
(20) and, in the case of fenoterol and isoprenaline, a re- 
duction in asthma control (21).With salmeterol, reduced 
protection against exercise-induced bronchoconstric- 
tion was shown to occur after 4 weeks of continuous 
twice-daily dosing (22). The significance of this effect is 
not clear, and the bronchodilator effect does not appear 
to alter with prolonged treatment. 
It has been shown in vitro that polymorphisms of the 
/G2-adreneoceptor affect the degree to which tolerance 
builds up and response to fiz-agonists may, therefore, be 
dependent on these structural changes in the receptor 
(23)./n vivo, patients genetically predisposed to receptor 
polymorphisms were treated for I week with either for- 
moterol 91tg twice daily or salmeterol 50#g twice daily 
(24). A significant degree of bronchoprotection was pre- 
sent 12 h after the first dose with both formoterol and 
salmeterol. Additionally, at the end of the dosing period 
there remained a significant degree of bronchoprotec- 
tion in both groups compared with placebo, with no sig- 
nificant differences between the active groups. 
In the Formoterol and Corticosteroids Establishing 
Therapy (FACET) study (25), the effects of giving formo- 
terol with budesonide on asthma exacerbations were 
studied for a period of 12 months. Patients receiving for- 
moterol 9#g and budesonide (100#g or 400pg) twice 
daily had significantly fewer severe and mild exacerba- 
tions than patients taking twice-daily budesonide 
(10011g or 400~g) alone; furthermore, these effects 
were maintained throughout the 12-month period. Dur- 
ing the first 2 days of the study, morning peak flow im- 
proved in the formoterol groups to a greater extent than 
subsequently; however, for the rest of the 12-month per- 
iod lung function remained stable and was considerably 
higher than in patients treated with corticosteroid only. 
A limited degree of tolerance was suggested as a possible 
cause of this effect, but was felt to have little or no clin- 
ical significance. 
Similar results were obtained in a study looking at the 
effects of formoterol 18 #g twice daily (delivered dose) 
given to patients using inhaled corticosteroids over a 6- 
month period (26). Again formoterol was effective in im- 
proving symptoms with no loss of asthma control during 
the 24-week treatment period. 
Patients in a real-life clinical setting have been studied 
in an open, prospective, surveillance study in which 54 
patients receiving formoterol were followed up for 5 
years (27). These results were compared with corre- 
sponding data from the previous 12 months. Patients with 
any degree of asthma were included in the study, 
although 52% of the patients were considered to have se- 
vere asthma. At baseline, patients were receiving regular 
treatment with a variety of medications, including short- 
acting fi2-agonists, inhaled corticosteroids and theophyl- 
line, but were still symptomatic and had frequent exacer- 
bations. Regular short-acting /G2-agonist therapy was 
replaced with individually determined doses of formoter- 
ol 12#g (metered dose) for maintenance therapy, admi- 
nistered with a Volumatic spacer. All changes to other 
medications were dictated by asthma control, with 
short-acting fi2-agonist therapy used as needed for 
symptom relief. At 5 years, the mean FEV, showed a sta- 
tistically significant improvement compared with values 
obtained before treatment with formoterol (P<0.05). 
Bronchial reversibility was maintained throughout the 
study period, and a high degree of stability of lung func- 
tion was demonstrated. Other aspects of asthma control 
improved significantly over the 5-year period--patients 
required lower doses of inhaled corticosteroids 
(P<0.005) and fewer interventions with systemic 
corticosteroids (P<0.001) (Table I). Fewer patients 
had exacerbations and the number of patients who 
regularly used an electric nebuliser for relief medication 
or required treatment with theophylline was signifi- 
cantly lower during treatment with formoterol 
compared with baseline values (P<0.001). No 
increase in the dose of formoterol was required 
during the study, suggesting that there was no develop- 
ment of tolerance. 
Another area of concern with long-term therapy is 
whether treatment with a/~2-agonist with long-acting 
properties could hide the symptoms of an impending ex- 
acerbation by masking any underlying inflammatory pro- 
cesses, resulting in a more severe exacerbation. Results 
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Table I, Dose offormoterol and concomitant medications in 54 patients receiving daily formoterol therapy over 5 years (27) 
m 
Patients (No.) 
Formoterol 
(inhalationslday) ~ 
Electric nebufiser 
(/~S-agonist/ 
Formoterol Previous 
therapy 
Baseline t year 
e 
s4 54 
0 2.5 (1-6) 
4l 6*** 
2years 
54 
2.5 (1-6) b 
4***  
3 years 4 years 5 years 
50 47 
Z5 (l-6)b 2.5 (I-6) b 
3"** I*** 
48 
2.5 (I-6)** 
1"** 
anticholinergk) (No) 
Theophy~line 31 9*** 
(>400 mg/daj (No.) 
Bedomethasone 
Users [No. (%)] 39 (72) 34 (63) 
Inhalations~day o'c 2,8 (0-6) 1.9 (0-6) **~ 
Systemic 
cor ticosteroids ~ 
Patients needing 27/49 (55) 12t49 (25) 
steroids [No. (%)] 
Interventions/ L6 (0-7) 0A (0-3)*** 
year °,c 
Therapeutic success 44.5 ÷ 139 : 795 + 10ft 
(VAS)e'( 
a[Vlean (range). 
9***  
84 (68) 
1.8 (0x6)*** 
SlS~ (Io) 
0.2 (0-2)*** 
78.7 ± 14.5 
6*** 
35 (70) 
2,2 (0-8)* 
S*** 4*** 
34 (72) 
1.9 (0=6)** 
11/47 (23) 6/45 03) 
0.2 (0-0"** 0.2 (0-4)*** 
7~ +14.6 78.7_+12.1 
36 (TS) 
L9 @-6)** 
9/46 (20) 
0.2 (0-2)*** 
80.2 + 10.4 
bNot signifiCant 
<Users and non-users. 
dWith0Ut 3 patients using systemic steroids on a regular basis. 
:eMean + SO. 
fVAS: visual analogue scale. ] 
* P < 0.05; **P < 0.005; ~ **P < 0.001, formoter0I therapy vs. p~evJous treatment 
i 
:i 
from the FACETstudy were analysed to compare the on- 
set, duration and severity of severe exacerbations (28) 
and it was found that there was no difference between 
patients treated with inhaled corticosteroids alone and 
those treated with inhaled corticosteroids and formo- 
terol. Further evidence that formoterol does not mask 
underlying airway inflammation was provided by Kips 
et a/. (29) who compared the effects of budesonide 
400 #g twice daily alone with budesonide 100/zg and for- 
moterol 9/tg, both twice daily, on markers of airway 
inflammation in induced sputum. No differences 
were found between the groups and the authors con- 
cluded that the addition of formoterol to a low dose of 
inhaled steroids in patients poorly controlled on current 
medication was preferable to increasing the dose of the 
steroid. 
CONCLUSIONS 
Formoterol has been demonstrated to be well tolerated 
when used as both regular and as-needed therapy in the 
treatment of asthma. At high doses, equivalent to those 
anticipated during as-needed use, formoterol has exhib- 
ited efficacy similar to that achieved with terbutaline, 
but with a lower incidence of systemic effects. Further- 
more, despite the long duration of bronchodilation pro- 
duced by formoterol, systemic effects were of a duration 
comparable with terbutaline. Additionally, the relative 
therapeutic index of formoterol compared with salbuta- 
mol has been estimated as 2.5. 
In long-term use, formoterol has been shown to be ef- 
fective for periods of up to 12 months with no build up of 
tolerance. A continued lack of desensitization has been 
observed in patients treated with formoterol for 5 years, 
during which time asthma control improved and fewer 
additional asthma treatments were required with no in- 
crease in the dose of formoterol. 
Although efforts should be made, as with all fi2-ago- 
nists, to ensure that patients do not exceed maximum 
recommended doses, it can be concluded from 
the available data that formoterol is safe for long- 
term use as regular treatment and as-needed relief 
medication. 
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